Acrivon Preclinical Data Suggests Strong Synergies for Lead Assets with Immunotherapies and ADCs
Event summary
- Acrivon will present three posters at AACR 2026 showing preclinical data for ACR-368 and ACR-2316 in combination with immune checkpoint inhibitors and ADC payloads.
- ACR-368 demonstrated strong synergy with Topo 1 inhibitors, a common ADC payload, and with anti-PD-L1 checkpoint inhibition.
- ACR-2316 combined with anti-PD-L1 showed complete tumor regression with durable immune memory in preclinical models.
- Data supports potential frontline clinical combinations for both ACR-368 and ACR-2316 with immune checkpoint inhibitors and ADCs.
The big picture
Acrivon's data highlights the growing importance of combination therapies in oncology, particularly as immuno-oncology and ADC therapies continue to dominate the treatment landscape. The company's proprietary AP3 platform positions it uniquely to identify and develop these synergistic combinations, potentially offering a competitive edge in the crowded oncology space. The strategic focus on frontline combinations could accelerate the clinical development timeline for ACR-368 and ACR-2316, addressing significant unmet needs in cancer treatment.
What we're watching
- Clinical Translation
- Whether the preclinical synergies observed with ACR-368 and ACR-2316 will translate into meaningful clinical benefits in combination therapies.
- Regulatory Pathway
- The pace at which Acrivon can advance these combination strategies through regulatory approvals, particularly given the Fast Track and Breakthrough Device designations for ACR-368.
- Competitive Positioning
- How Acrivon's proprietary AP3 platform differentiates its drug development approach in the competitive immuno-oncology and ADC therapy landscapes.
Related topics